Jasmeet Singh

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

Shanu Modi, William Jacot, Toshinari Yamashita et al. · New England Journal of Medicine · 2022 · 2.3K citations · Full text

Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors

Junji Tsurutani, Hiroji Iwata, Ian E. Krop et al. · Cancer Discovery · 2020 · 337 citations · Full text

Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study

Eric Van Cutsem, Maria Di Bartolomeo, Elizabeth Smyth et al. · The Lancet Oncology · 2023 · 203 citations · Full text

Disease Progression, Gastrointestinal Oncology, Medicine +8

Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies

Charles A. Powell, Shanu Modi, Hiroji Iwata et al. · ESMO Open · 2022 · 202 citations · Full text

Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01)

Cristina Saura, Shanu Modi, Ian E. Krop et al. · Annals of Oncology · 2023 · 96 citations · Full text